Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline
January 20, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones
January 13, 2022 07:00 ET
|
ONL Therapeutics
– Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) – –...
Vitrectomy Devices Market Size ($2,003.24Mn by 2028) Lead by Vitrectomy Machines (6.5% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
November 29, 2021 06:48 ET
|
The Insight Partners
New York, Nov. 29, 2021 (GLOBE NEWSWIRE) -- According to our new research study on Vitrectomy Devices Market Size, Share, Revenue, Growth, Trends, Forecast to 2028 - COVID-19 Impact and Global...
Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Eyenuk Announces Publication of Strong EyeArt® Pivotal Clinical Trial Results in JAMA Network Open
November 15, 2021 14:38 ET
|
Eyenuk, Inc.
LOS ANGELES, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...
Cross Keys Capital Advises Retina Associates of Utah, P.C., on Its Partnership with Retina Consultants of America
November 04, 2021 16:02 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, FL, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Cross Keys Capital, a leading investment bank to physician group practices and healthcare service and technology companies, is pleased to...
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
November 01, 2021 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Newly Formed Lanier Biotherapeutics Enters into License Agreement with Alloy Therapeutics
October 05, 2021 08:00 ET
|
Lanier Biotherapeutics
BOGART, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, and Type 2...
Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference
September 30, 2021 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Worldwide Choroidal Neovascularization Industry to 2026 - Featuring Novartis, Pfizer and Regeneron Pharmaceuticals Among Others
September 30, 2021 06:53 ET
|
Research and Markets
Dublin, Sept. 30, 2021 (GLOBE NEWSWIRE) -- The "Choroidal Neovascularization Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...